v3.26.1
Segment Information - Summary of Segment Expenses and Reported Segment Net Loss (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Revenue from customers $ 0   $ 965   $ 2,830 $ 1,276
Revenue from licensing agreements 27,778   0   27,778 0
Early-stage research and development [1] (703)   (688)   (1,120) (1,530)
Late-stage research and development [2] (23,347)   (13,288)   (46,282) (26,948)
General and Administrative (5,618)   (5,556)   (12,025) (10,608)
Total operating expenses (29,668)   (19,532)   (59,427) (39,086)
Interest and other income, net 221   1,207   1,032 2,087
Change in fair value of 2023 Common Warrants 2,976   1,682   6,371 63,176
Income (loss) before income tax 1,307   (15,678)   (21,416) 27,453
Income tax provision (2,811)   (185)   (3,128) (228)
Net (loss) income $ (1,504) $ (23,040) $ (15,863) $ 43,088 $ (24,544) $ 27,225
[1]

(1) Early-stage research and development includes costs incurred from Discovery programs.

[2]

(2) Late-stage research and development includes costs incurred from Phase 1 and Phase 2 clinical trial programs.